Please login to the form below

Not currently logged in
Email:
Password:

Dr Maurice Chagnaud appointed as new CEO of Polpharma

Will take the reins at the Polish pharmaceutical group week
Polpharma Maurice Chagnaud

Polish pharmaceutical group Polpharma has appointed Dr Maurice Chagnaud as its new CEO.

He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia & CIS.

Prior to that Dr Chagnaud held senior roles at Teva, Mylan and Merck Generics during a career that has so far seen him amass more than 20 years of European pharma management experience.

Polpharma operates across Europe, CIS and Central Asia and has manufacturing subsidiaries in Poland, Russia and Kazakhstan. It's the largest Polish pharmaceutical group and wants Dr Chagnaud to help it become a regional leader in CEE, CIS and Central Asia.

Jerzy Starak, chairman of Polpharma's supervisory board, said: “Polpharma's strategic goal is to become a regional leader and grow outside of our current boundaries. We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva and Lupin, where his achievements included building regional strategies and transforming organisations to meet new challenges.

“I am confident that he will manage Polpharma effectively, identify and pursue new opportunities, and motivate our team to deliver outstanding performance to secure the long-term growth of our group.”

As Polpharma CEO Dr Chagnaud will succeed Markus Sieger, who has been delegated by the Supervisory Board to exercise supervision over the company for the last six months, and who will remain a member of the Supervisory Board.

30th September 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics